168077-29-0

Basic information

• Product Name: 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride
• Synonyms: 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride
• CAS NO: 168077-29-0
• Molecular Weight: 224.69
• Mol File: 168077-29-0.mol

Chemical Properties

• CAS DataBase Reference: 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride(168077-29-0)
• EPA Substance Registry System: 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride(168077-29-0)

Safety Data

• Hazardous Substances Data: 168077-29-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4-pyridinyl)piperidin-4-yl carbonyl chloride is used as a reagent for the acylation of amines and other nucleophiles, facilitating the formation of amides. Its high reactivity makes it a valuable component in synthetic chemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(4-pyridinyl)piperidin-4-yl carbonyl chloride is utilized in the production of various pharmaceutical compounds, contributing to the development of new drugs and therapies.
Used in the Synthesis of Biologically Active Molecules:
1-(4-pyridinyl)piperidin-4-yl carbonyl chloride serves as a versatile building block for the synthesis of a wide range of biologically active molecules, further expanding its applications in the field of medicinal chemistry and drug discovery.

Upstream product

• 93913-86-1 4-carboxy-N-(4'-pyridino) piperidine 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 179051-74-2 1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine 
• 210962-09-7 1-(pyridin-4-yl)piperidine-4-carboxylic acid hydrochloride 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 905576-52-5 2-{3-[[(tert-butoxycarbonyl)amino](imino)methyl]phenoxy}ethyl 1-pyridine-4-ylpiperidine-4-carboxylate 
• 280769-25-7 5-chloro-N-(5-fluoropyridin-2-yl)-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide hydrochloride 
• 280769-01-9 N-(5-chloropyridin-2-yl)-5-fluoro-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide hydrochloride 
• 280768-99-2 N-(5-chloropyridin-2-yl)-4-fluoro-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide hydrochloride 
• 280768-98-1 4-Chloro-N-(5-chloropyridin-2-yl)-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide Hydrochloride 
• 280768-70-9 N-(5-chloropyrimidin-2-yl)-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide 
• 280768-66-3 N-(5-chloropyridin-2-yl)-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide hydrochloride 
• 280769-00-8 5-chloro-N-(5-chloropyridin-2-yl)-2-[[1-(4-pyridinyl)piperidin-4-ylcarbonyl]amino]benzamide hydrochloride 
• 280771-68-8 2-amino-N-(6-chloropyridazin-3-yl)benzamide 
• 179050-10-3 1-(4-bromophenylsulphonyl)-4-[1-(pyridin-4-yl)piperidin-4-ylcarbonyl]piperazine 

Relevant articles and documents

NOVEL BENZAMIDINE COMPOUND

A novel compound, or a pharmaceutically acceptable salt thereof, represented by the formula (1) wherein the characters are as defined in the description. Thus, there can be provided an activated blood coagulation factor X inhibitor and a novel anti(blood)

AROMATIC AMIDES

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase

A novel series of 4-piperidinopyridines and 4-piperidinopyrimidines showed potent and selective inhibition of rat 2,3-oxidosqualene cyclase-lanosterol synthase (OSC) (e.g. 26 IC50 rat = 398 ± 25 nM, human = 112 ± 25 nM) and gave selective oral inhibition of rat cholesterol biosynthesis (26 ED80 = 1.2 ± 0.3 mg/kg, n = 5; HMGCoA reductase inhibitor simvastatin ED80 = 1.2 ± 0.3 mg/kg, n = 5). The piperidinopyrimidine OSC inhibitors have a significantly lower pKa than the corresponding pyridine or the previously reported quinuclidine OSC inhibitor series. This indicates that other novel OSC inhibitors may be found in analogues of this series across a broader pKa range (6.0-9.0). These series may yield novel hypocholesterolemic agents for the treatment of cardiovascular disease.

Use of oxido-squalene cyclase inhibitors to lower blood cholesterol

PCT No. PCT/GB96/01985 Sec. 371 Date Feb. 13, 1998 Sec. 102(e) Date Feb. 13, 1998 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/06802 PCT Pub. Date Feb. 27, 1997A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T1, T2 and T3 are selected from CH and N; provided that T2 and T3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.

Aminoheterocyclic derivatives as antithrombotic or anticoagulant

The invention concerns compounds of formula (I), wherein each of G1, G2 and G6 is CH or n; m is 1 or 2; R1 includes hydrogen, halogeno and (1-4C)alkyl; M1 is a group of formula: NR2 -L1 -T1 R3, in which R2 and R3 together form a (1-4C)alkylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2 R4)r -L2 T3 R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.